COURSE ID 2650

OTC Stability Program for FDA Compliance

AVAILABLE Live
Date(s) and Time:
March 18, 2024 - March 19, 2024
9:00am EDT - 12:30pm EDT
Duration: 6 Hours

Can't attend the live course?
Select the on-demand option during registration, and we will automatically send you the recording when it is ready.

Course Instructor

David E. Wiggins

Early-Bird Offer

Limited Availability until February 7, 2024

$ 880
Price
$ 980
Discounts: We offer a 10% group discount when you register 2 or more attendees (up to 10). Contact us for groups over 10.

Course description

View Course Outline

In 2006, FDA withdrew both their approved 1987 Stability Guideline and their draft 1998 Stability Guidance and referred industry to the ICH Stability Guidances. With the ICH guidance documents covering New Chemical Entities (NCEs) and their associated drug products, there was no guidance provided for OTC drugs covered by an ANDA or an OTC monograph. In 2014, FDA issued Guidance for Stability testing requirements for all drug products covered by an ANDA, but no guidance has been provided for OTC monograph drug products.

As a result, strictly following the ICH stability guidance for NCEs is unwarranted and ignores the significant database of information that is typically available for OTC drug products. For OTC drug products covered by an OTC monograph, there is frequently years of proven experience with the drug substance as well as the drug product. It is this body of data that can often be used to justify a pre-market stability program.

This accredited course will provide an understanding of how the pre-market stability programs can be successfully managed while minimizing the overall timeline. Lectures will address the seven key GMP aspects of a stability program along with all of the relevant stability guidelines that cover drug product stability. Accelerated testing that allows the marketing of a new OTC drug product prior to the generation of long-term, real-time stability data and confirmation of the stability projections will also be covered.

Upon completion of this course, you will be able to:

  • Establish the stability of an OTC drug product following a fully GMP compliant program
  • Describe how the stability would be established for an OTC drug product covered by an OTC Monograph
  • Prepare stability protocols that incorporate all cGMP requirements and are consistent with the intended purpose
Register

You will be redirected to our secure system.

This course is intended for individuals who have the responsibility for establishing the stability of Over-the-Counter (OTC) drug products.

This course will benefit individuals in:

  • R&D
  • QA/QC
  • Technical Operations
  • Contract Laboratories

This course will also benefit those individuals with similar responsibilities who work in the cosmetic and personal care industries.

Course Instructor

David E. Wiggins

Analytical/Stability Consultant

David E. Wiggins’s Courses

Accreditation

Team Training

When you need on-site attention, we’re not just here to help, we’re there to help—right by your side.

Individual courses are remarkably effective. But sometimes when you have a specific need, it helps to have expert guidance right in the room with you and your team.

In that case, we’re happy to design a custom training for your entire team, whether online—or on-site.

Learn more

We’ve rebranded! CfPA is now COBBLESTONE